Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing and/or treating diabetes mellitus

A technology of diabetes and composition, which is applied in the direction of drug combination, metabolic disease, medical formula, etc., can solve the problems of unstable quality control of traditional Chinese medicine, processing of crude preparations, unknown active ingredients, etc., and achieve the protection of islet cells, great application prospects, The effect of simple process

Active Publication Date: 2013-09-11
正北芪产业科技(深圳)有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no ideal traditional Chinese medicine monomer or traditional Chinese medicine compound that can replace the classic oral hypoglycemic western medicine to stably and effectively lower blood sugar.
In addition, most of these traditional Chinese medicines on the market are used together with other traditional Chinese medicines, which makes the quality control of Chinese medicines relatively unstable and the reproducibility of curative effects is poor.
At present, there are many kinds of patents on the treatment of diabetes with Astragalus, Hawthorn and other traditional Chinese medicines, but most of the crude drugs are not clear, or are low-level crude preparations, and it is impossible to effectively control the quality standards of their production processes, and their specific active ingredients are not known. Why, thus limiting its further application, it is also difficult to form a large-scale production effect and connect with the international market, and it is also difficult to meet the actual needs of the increasing number of diabetic patients at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1, the preparation of medicine for treating diabetes

[0045] The astragalus polysaccharide is prepared from astragalus root through conventional extraction process and spray drying, and the polysaccharide content is 50% after testing. The specific method is as follows: take 500 g of astragalus decoction pieces (Shenzhen Lifeng Pharmaceutical Company, batch number 111128), add 10 times the amount of distilled water to reflux for extraction for 2 hours, filter, add 10 times the amount of water to extract again for 1 hour, and filter. The two filtrates were combined and concentrated to 500ml, added 3 times the volume fraction of 95% ethanol solution, left standing overnight at low temperature, centrifuged, suction filtered, and vacuum-dried to obtain astragalus polysaccharide.

[0046] Hawthorn flavonoids are prepared from hawthorn fruit through conventional extraction process and spray drying, and the flavonoid content is 30% after testing. The specific metho...

Embodiment 2

[0047] Embodiment 2, the influence of the drug ratio of different proportions on the oral glucose tolerance test of diabetic mice

[0048] 1. Production of NIH mouse diabetes model

[0049] NIH male mice (about 20 g) were fasted for 24 hours, and injected intraperitoneally once with 100 mg / kg streptozotocin (Streptozotocin, Sigma Company, USA) (streptozotocin was freshly prepared with ice-bathed citrate buffer solution in advance). reconstituted (0.1M, pH 4.5), injected within 5 minutes). After 10 days, the mice with a stable increase in blood sugar (blood sugar above 11.1 mmol / L) were the NIH mouse diabetes models.

[0050] 2. Oral glucose tolerance test

[0051] After overnight fasting of diabetic mice, 2.5g / kg glucose solution was administered into the stomach, and blood was collected from the eye sockets of the mice at time points 0, 0.5, 1 and 2 hours respectively, and the serum was centrifuged to detect the glucose concentration, and the blood glucose and The change i...

Embodiment 3

[0054] Embodiment 3, the drug effect of the medicine for treating diabetes

[0055] 1. Production of NIH mouse diabetes model

[0056] With embodiment 2.

[0057] 2. Administration of NIH mouse diabetes model

[0058] After successful screening of diabetes models, grouping (n=10) was carried out, and intragastric administration was carried out according to the following drug components for four consecutive weeks.

[0059] Astragalus polysaccharides and hawthorn flavonoids mixed treatment group (HS): In the NIH mouse diabetes model, astragalus polysaccharides and hawthorn flavonoids were mixed at a net content ratio of 1:1, and the net content was 200 mg / kg / day for intragastric administration. medicine.

[0060] Astragalus polysaccharide treatment group alone (H): In the NIH mouse diabetes model, astragalus polysaccharide was administered orally with a net content of 200 mg / kg / day.

[0061] Hawthorn flavonoids alone treatment group (S): In the NIH mouse diabetes model, hawt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for preventing and / or treating diabetes mellitus. The pharmaceutical composition is prepared from hawthorn flavone and astragalus polysaccharide, wherein the mass ratio of the hawthorn flavone to the astragalus polysaccharide is (4:1) to (1:2), preferably (2:1) to (1:2). A pharmacodynamic test shows that the pharmaceutical composition has significant effects of reducing fasting blood-glucose and postprandial blood sugar of the diabetes mellitus, improving insulin sensitivity, improving symptoms of diabetes and restraining disturbance of carbohydrate metabolism caused by fatty food; the action mechanism is related to protection and repair of an islet cell function while the hawthorn flavones and the astragalus polysaccharide can be independently dosed; no ideal antidiabetic effect is displayed.

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing and / or treating diabetes. Background technique [0002] Diabetes is a chronic glucose metabolism disorder that seriously affects human health. According to the 2010 National Diabetes Survey, the prevalence of diabetes among adults in my country is 9.7%, 10.6% for men and 8.8% for women. Especially in recent years, the incidence of diabetes has shown a rapid upward trend with the improvement of people's living standards. my country is in a period of high incidence of diabetes, and diabetes has become one of the major public health problems in our country. Although there are effective drugs for controlling blood sugar in diabetes, most of them still treat the symptoms but not the root cause. [0003] At present, the mechanism of action of hypoglycemic drugs is mainly manifested in the following aspects: 1. to supplement insulin levels, such as insulin injection preparations; 2. to inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/734A61P3/10A61K31/715
Inventor 谢伟东张雅鸥许乃寒
Owner 正北芪产业科技(深圳)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com